Core Viewpoint - The company has initiated the first patient dosing in a Phase III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight conditions in China, with plans to recruit approximately 800 participants by September 30, 2025 [1] Company Summary - The company is focused on developing Isuparaglutide α as a treatment for obesity and overweight [1] - The Phase III clinical trial represents a significant step in the product's development pipeline [1] Industry Summary - The clinical trial is part of a broader trend in the pharmaceutical industry towards addressing obesity and related health issues [1] - The recruitment of 800 participants indicates a robust approach to validating the efficacy and safety of the treatment [1]
银诺医药-B(02591)已在中国完成核心产品(即依苏帕格鲁肽α)用于治疗肥胖和超重的III期临床试验的首例患者给药